Merck’s Covid pill results raise hopes for developing world

As Merck & Co. races ahead with an experimental pill that could play a pivotal role in the fight against Covid-19, efforts are intensifying to bring the drug to developing countries that have struggled to vaccinate their populations.

The global health agency Unitaid and its partners hope to reach an agreement as soon as next week to secure the first supplies of the antiviral treatment for lower- and middle-income nations, Philippe Duneton, its executive director, said in an interview. Unitaid has been in discussions with the company and generic manufacturers, he said.

“This is really what we’ve waited for all these months,” he said. “There is a window of hope with this treatment, and now we need to collectively make it work for people” in less well-to-do countries.

On the vaccine front, lower-income nations have been left behind. About nine months after the arrival of Covid shots, more than 55 countries have yet to vaccinate 10% of their populations. More than two dozen nations are below 2%.

If the medication hits the market, it could be a turning point in the pandemic. Results Friday were so positive that Merck and partner Ridgeback Biotherapeutics LP — in consultation with independent trial monitors and the U.S. Food and Drug Administration — elected to stop enrolling patients and begin the process of gaining regulatory clearance. Merck plans to submit the data to other regulators worldwide.

Licensing Deals

The company earlier this year announced that it had signed non-exclusive voluntary licensing agreements for the drug with five generic manufacturers in India in a bid to accelerate availability in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.

Potentially the drug could be very cheap to manufacture and available at a low cost in developing nations, benefiting millions of people, Andrew Hill, a senior research fellow at the University of Liverpool, wrote in an email.

“This could be a major advance in the treatment of Covid-19,” he said.

The company said in a statement that it expects to produce 10 million courses of treatment by year-end, with more expected in 2022. In June, the company agreed to a $1.2 billion supply deal with the U.S. government, under which it would provide 1.7 million courses of the treatment.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor